Clinical Progress in Hepatic Targeting for Novel Prophylactic Therapies in Hereditary Angioedema

被引:2
作者
Riedl, Marc A. [1 ,4 ]
Bordone, Laura [2 ]
Revenko, Alexey [2 ]
Newman, Kenneth B. [2 ]
Cohn, Danny M. [3 ]
机构
[1] Univ Calif San Diego, Div Allergy & Immunol, La Jolla, CA USA
[2] Ionis Pharmaceut, Carlsbad, CA USA
[3] Univ Amsterdam, Dept Vasc Med, Amsterdam Cardiovasc Sci, Amsterdam UMC, Amsterdam, Netherlands
[4] Univ Calif San Diego, Div Allergy & Immunol, 8899 Univ Ctr Ln,Ste 230, San Diego, CA 92122 USA
关键词
ASO; Hereditary angioedema; Liver; Antisense oligonucleotide; siRNA; Gene therapy; CRISPR/Cas systems; PLASMA KALLIKREIN INHIBITOR; ANTISENSE OLIGONUCLEOTIDE; GENE-THERAPY; CHALLENGES; MANAGEMENT; UPDATE; LIVER; HAE;
D O I
10.1016/j.jaip.2023.12.025
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Hereditary angioedema (HAE) is typically caused by a deficiency of the protease inhibitor C1 inhibitor (C1INH). The absence of C1INH activity on plasma kallikrein and factor XIIa leads to overproduction of the vasoactive peptide bradykinin, with resulting angioedema. As the primary site of C1INH and prekallikrein production, the liver is recognized as an important therapeutic target in HAE, leading to the development of hepaticfocused treatment strategies such as GalNAc-conjugated antisense technology and gene modification. This report reviews currently available data on hepatic-focused interventions for HAE that have advanced into human trials. Donidalorsen is an investigational GalNAc3-conjugated antisense oligonucleotide that binds to prekallikrein mRNA in the liver and reduces the expression of prekallikrein. Phase 2 data with subcutaneous donidalorsen demonstrated a significant reduction in HAE attack rate compared with placebo. Phase 3 trials are underway. ADX-324 is a GalNAc3-conjugated short-interfering RNA being investigated in HAE. BMN 331 is an investigational AAV5-based gene therapy vector that expresses wild-type human C1INH and is targeted to hepatocytes. A single intravenous dose of BMN 331 is intended to replace the defective SERPING1 gene and enable patients to produce functional C1INH. A first-in-human phase 1/2 study is ongoing with BMN 331. NTLA-2002 is an investigational in vivo clustered regularly interspaced short palindromic repeats/Cas9based therapy designed to knock out the prekallikrein-coding KLKB1 gene in hepatocytes; a phase 1/2 study is ongoing. Findings from these and other ongoing studies are highly anticipated with the expectation of expanding the array of treatment options in HAE. (c) 2024 American Academy of Allergy, Asthma & Immunology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/ oligonucleotide; siRNA; Gene therapy; CRISPR/Cas systems
引用
收藏
页码:911 / 918
页数:8
相关论文
共 63 条
  • [21] ClinicalTrials.gov, CSL312 (Garadacimab) in the prevention of hereditary angioedema attacks NCT04656418
  • [22] Evaluation of patient-reported outcome measures for on-demand treatment of hereditary angioedema attacks and design of KONFIDENT, a phase 3 trial of sebetralstat
    Cohn, Danny M.
    Aygoeren-Puersuen, Emel
    Bernstein, Jonathan A.
    Farkas, Henriette
    Lumry, William R.
    Maurer, Marcus
    Zanichelli, Andrea
    Iverson, Matthew
    Hao, James
    Smith, Michael D.
    Yea, Christopher M.
    Audhya, Paul K.
    Riedl, Marc A.
    [J]. CLINICAL AND TRANSLATIONAL ALLERGY, 2023, 13 (09)
  • [23] Antisense Inhibition of Prekallikrein to Control Hereditary Angioedema
    Cohn, Danny M.
    Viney, Nicholas J.
    Fijen, Laure M.
    Schneider, Eugene
    Alexander, Veronica J.
    Xia, Shuting
    Kaeser, Gwendolyn E.
    Nanavati, Charvi
    Baker, Brenda F.
    Geary, Richard S.
    Levi, Marcel
    Meijers, Joost C. M.
    Stroes, Erik S. G.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (13) : 1242 - 1247
  • [24] Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
    Craig, Timothy J.
    Reshef, Avner
    Li, H. Henry
    Jacobs, Joshua S.
    Bernstein, Jonathan A.
    Farkas, Henriette
    Yang, William H.
    Stroes, Erik S. G.
    Ohsawa, Isao
    Tachdjian, Raffi
    Manning, Michael E.
    Lumry, William R.
    Saguer, Inmaculada Martinez
    Aygoeren-Puersuen, Emel
    Ritchie, Bruce
    Sussman, Gordon L.
    Anderson, John
    Kawahata, Kimito
    Suzuki, Yusuke
    Staubach, Petra
    Treudler, Regina
    Feuersenger, Henrike
    Glassman, Fiona
    Jacobs, Iris
    Magerl, Markus
    [J]. LANCET, 2023, 401 (10382) : 1079 - 1090
  • [25] Integrated Assessment of the Clinical Performance of GalNAc3-Conjugated 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience
    Crooke, Stanley T.
    Baker, Brenda F.
    Xia, Shuting
    Yu, Rosie Z.
    Viney, Nicholas J.
    Wang, Yanfeng
    Tsimikas, Sotirios
    Geary, Richard S.
    [J]. NUCLEIC ACID THERAPEUTICS, 2019, 29 (01) : 16 - 32
  • [26] Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On-Demand Treatment for Hereditary Angioedema
    Davie, Rebecca L.
    Edwards, Hannah J.
    Evans, D. Michael
    Hodgson, Simon T.
    Stocks, Michael J.
    Smith, Alun J.
    Rushbrooke, Louise J.
    Pethen, Stephen J.
    Roe, Michael B.
    Clark, David E.
    McEwan, Paul A.
    Hampton, Sally L.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (20) : 13629 - 13644
  • [27] Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug
    Debacker, Alexandre J.
    Voutila, Jon
    Catley, Matthew
    Blakey, David
    Habib, Nagy
    [J]. MOLECULAR THERAPY, 2020, 28 (08) : 1759 - 1771
  • [28] Overcoming cellular barriers for RNA therapeutics
    Dowdy, Steven F.
    [J]. NATURE BIOTECHNOLOGY, 2017, 35 (03) : 222 - 229
  • [29] Immunogenicity and toxicity of AAV gene therapy
    Ertl, Hildegund C. J.
    [J]. FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [30] IONIS-PKKRx a Novel Antisense Inhibitor of Prekallikrein and Bradykinin Production
    Ferrone, Jason D.
    Bhattacharjee, Gourab
    Revenko, Alexey S.
    Zanardi, Thomas A.
    Warren, Marshelle S.
    Derosier, Frederick J.
    Viney, Nicholas J.
    Pham, Nguyen C.
    Kaeser, Gwendolyn E.
    Baker, Brenda F.
    Schneider, Eugene
    Hughes, Steven G.
    Monia, Brett P.
    MacLeod, A. Robert
    [J]. NUCLEIC ACID THERAPEUTICS, 2019, 29 (02) : 82 - 91